National Policy: Access to Government Funded Immunoglobulin Products in Australia

Online version of the Criteria

An adaptation of the second edition of the Criteria has been included in BloodSTAR and is applicable for all states and territories except NSW from 2016. The Criteria as they appear in BloodSTAR (version 2.1) can be viewed here.

The inclusion of new ‘evidence items’ fields within the Criteria version 2.1 in BloodSTAR does not change the basis for approval of authorisation of Ig product.

The NBA has developed a national policy for access to Ig products funded under the national blood arrangements in Australia.  This document clarifies the roles and responsibilities for all stakeholders involved in the management of immunoglobulin, including:

  • roles, responsibilities, authority and accountability of those involved in requesting authorisation, authorising, supplying managing and using immunoglobulin products,
  • standardised national patient treatment access and review arrangements and processes 
  • coordinated and consistent in-hospital ordering and management to improve transparency of product inventory, ensure that product is provided to approved patients only and to reduce expiry related wastage.

The policy should be read in conjunction with the Criteria for the clinical use of immunoglobulin in Australia.

The policy was first released in 2014 and revised for the BloodSTAR release in 2016. 

The Policy will undergo an additional review to coincide with the release of Version 3 of the Criteria.

All states (except NSW) use the second edition (July 2016)

Cover image of National Policy: Access to Government Funded Immunoglobulin Products in Australia  (pdf)

New South Wales use first edition (November 2014)

 (pdf)

Keep up to date

Keep up to date with the latest Immunoglobulin Governance updates - create a BloodPortal account and from the home page click on ‘My Subscriptions’ and ‘Subscribe’ to Immunoglobulin. The latest update is available at Ig Governance Criteria and Progress Updates.